Overview

Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate if continuous subcutaneous delivery of interferon alfa-2b using an external drug pump in combination with the use of oral ribavirin provides a safe and effective treatment for patients with chronic hepatitis C infection as compared to patients who receive standard treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Medtronic Corporate Technologies and New Ventures
Treatments:
Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2b
Ribavirin